- $55.15m
- $64.20m
- $0.20m
Brief: Clene Inc On Aug 1 Got Written Notice From Nasdaq For Last 30 Business Days, Bid Price For Co's Common Stock Closed Below Minimum Requirement
Brief: Clene Welcomes New Shareholder Base And Announces Closing Of Underwritten Public Offering Of $40 Mln
U.S. STOCKS ON THE MOVE-Squarespace, NaaS Technology, American International Group
U.S. STOCKS ON THE MOVE-Virgin Galactic Holdings, Hospital stocks, Dollar General
U.S. STOCKS ON THE MOVE-Novavax, Nvidia, Humana
Clene prices $40 mln equity offering after ALS drug update, shares tumble
Brief: Clene Announces Pricing Of $40 Million Public Offering
U.S. STOCKS ON THE MOVE-iRobot, Nikola, Adobe
Brief: Clene Received Notice From Nasdaq Regarding Regained Compliance With Nasdaq Listing Rule
Clene launches equity offering after ALS drug update, shares tumble
Brief: Clene's CNM-Au8 Shows Statistically Significant Difference in Plasma Neurofilament Light (NfL) Levels
Clene's ALS drug shows reduction in disease indicator in mid-stage trial (updated)
Clene's ALS drug shows reduction in disease indicator in mid-stage trial
Brief: Clene Receives Notice Of Delisting Or Failure To Satisfy A Continued Listing Rule From Nasdaq
Brief: Clene Awarded Grant From National Multiple Sclerosis Society To Advance Development Of CNM-Au8 In Non-Active Progressive Multiple Sclerosis
Clene Inc. reports results for the quarter ended in March - Earnings Summary
Brief: Clene Inc. - QTRLY Loss Per Share $0.15
Brief: Clene Inc's Stockholders Adopted Fourth Amended, Restated Certificate Of Incorporation To Increase Number Of Authorized Shares Of Common Stock To 300 Million
Clene Inc. expected to post a loss of 14 cents a share - Earnings Preview